Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.43 |
| ▸ | FABP4 | P15090 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23402853 | 0.79 | SMN1; SMN2 (0.41) | PTGIRFABP4SMN1; SMN2HSD17B10ALOX15 | |
| Isofezolac SCHEMBL25481 | 0.79 | ALDH1A1 (0.52) | PTGIRPTGDR2FABP4SMN1; SMN2KDM4E | |
| SCHEMBL6608161 | 0.76 | SMN1; SMN2 (0.42) | PTGIRFABP4SMN1; SMN2HSD17B10ALOX15 | |
| SCHEMBL23403471 | 0.74 | FYN (0.40) | SMN1; SMN2HSD17B10ALOX15KDM4EALDH1A1 | |
| SCHEMBL23400022 | 0.73 | CASP1 (0.40) | FABP4HSD17B10ALOX15KDM4EALDH1A1 | |
| SCHEMBL23399567 | 0.73 | RAB9A (0.43) | PTGIRSMN1; SMN2 | |
| SCHEMBL23403196 | 0.73 | RAB9A (0.43) | PTGIRSMN1; SMN2 | |
| SCHEMBL8890041 | 0.71 | CSF1R (0.46) | PTGIRSMN1; SMN2HSD17B10ALOX15KDM4E | |
| SCHEMBL23400212 | 0.71 | CYP1A2 (0.41) | SMN1; SMN2HSD17B10ALOX15KDM4EALDH1A1 | |
| SCHEMBL23399087 | 0.71 | MEN1 (0.40) | KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3693381-B1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2025-09-03 | — | — | EP | disclosed |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RES INST (US) | 2025-05-22 | — | — | US | disclosed |
| EP-0123541-A1 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
| EP-0084822-A2 | Diphosphonic acid derivatives and pharmaceutical preparations containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-08-03 | — | — | EP | disclosed |
| US-4391814-A | Derivatives of antiphlogistically effective carboxylic acids, their preparation and medicinal use | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-07-05 | — | — | US | disclosed |
| EP-0054812-A1 | Derivatives of antiphlogistically active carboxylic acids, their preparation and medical application | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | PTGIR 439/4885PTGDR2 411/4885FABP4 157/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | PTGIR 441/4885PTGDR2 359/4885FABP4 202/4885 |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | PTGIR 1161/4885PTGDR2 831/4885FABP4 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.